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Abstract
Mitochondrial trafficking deficits have been implicated in the pathogenesis of several neurological diseases, including
Alzheimer’s disease (AD). The Ser/Thre kinase GSK3b is believed to play a fundamental role in AD pathogenesis. Given that
GSK3b substrates include Tau protein, here we studied the impact of GSK3b on mitochondrial trafficking and its
dependence on Tau protein. Overexpression of GSK3b in neurons resulted in an increase in motile mitochondria, whereas a
decrease in the activity of this kinase produced an increase in mitochondria pausing. These effects were dependent on Tau
proteins, as Tau (2/2) neurons did not respond to distinct GSK3b levels. Furthermore, differences in GSK3b expression did
not affect other parameters like mitochondria velocity or mitochondria run length. We conclude that GSK3B activity
regulates mitochondrial axonal trafficking largely in a Tau-dependent manner.
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Introduction
Axonal transport is essential for neuron function and viability.
The axon is mostly devoid of the machinery for the synthesis of
proteins and lipids and for the biogenesis of most organelles. Thus
efficient axonal transport is required to supply these components
and to move organelles from the cell body to the axonal distal
region. Several neurodegenerative diseases, like amyotrophic
lateral sclerosis, Huntington’s disease, Charcot-Marie-Tooth
disease, and Alzheimer’s disease, exhibit axonal transport defects
[1]. In Huntington’s disease, pathogenic huntingtin inhibits axonal
transport by activating a kinase that modifies the motor protein
kinesin involved in transport [2,3]. Also, mutations in molecular
motors have been reported in Charcot-Marie-Tooth disease [3].
In Alzheimer’s disease (AD), beta amyloid peptide (Ab) alters
axonal transport [4,5,6] through a mechanism involving kinase
activation and modification of proteins that may regulate axonal
transport [7]. Moreover, Tau protein is required for Ab-induced
defects in axonal transport [8].
Several kinases and substrates may be involved in axonal
transport. For example, CK1 activates minus-end-directed
transport of organelles along microtubules [9]. Another kinase
that may participate in plus-end-directed transport in axons is
GSK3. In AD, Ab peptide binds to Wnt [10], insulin [11] and
NMDA [12,13] receptors, all of which promote an increase in
GSK3 activity, and this kinase phosphorylates kinesin-1, thereby
impairing transport [14]. However, the subsequent GSK3
activation may promote tau phosphorylation, thereby preventing
its interaction with microtubules or facilitating its interaction with
kinesin-1 [15]. The participation of tau in axonal transport has
been previously described, indicating that it interferes with the
binding of motor proteins to microtubules [16]. Also, tau protein is
required for Ab-induced defects in axonal transport [8]. However,
little is known about the contribution of phosphotau to this
transport. It has been suggested that tau modified by kinases other
than GSK3 detaches from microtubules to facilitate organelle
transport [17]. Here we studied the participation of GSK3b in
mitochondrial trafficking and the dependence of the effects
observed on tau protein, a GSK3b substrate. Our results indicate
that GSK3 activity increases the number of mitochondria
transported through the axon in a tau-dependent manner.
Materials and Methods
Neuronal primary culture and transfection
E16 mouse brains were dissected in PBS containing 0.6%
glucose and the hippocampi were obtained. After trypsin
(Invitrogen, Carlsbad, CA) and DNase treatment (Roche Diag-
nostics), tissue pieces were dissociated by gentle sweeping. Cells
were then counted and seeded onto 0.5 mg/ml poly-L-lysine
(Sigma-Aldrich)-coated coverslips (for immunocytochemistry) or
35-mm Fluorodish plates (World Precision Instruments, Inc) for
live-imaging in neurobasal medium (Gibco) containing 2 mM
glutamax, 120 mg/ml Penicillin, 200 mg/ml Streptomycin and
B27 supplement (Invitrogen, Carlsbad, CA), and were maintained
at 37uC in the presence of 5% CO2. Cells were cultured for 7
days. Neuronal transfection was carried out at 4 DIV using
Lipofectamine 2000 (Invitrogen) following the manufacturer’s
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27686Figure 1. GSK3b overexpression increases the percentage of motile mitochondria. A–F: Representative images of primary cultured neuron
axons showing the movement of some mitochondria. Motile mitochondria are indicated with colored triangles. Time interval between photographs
is 10 seconds. GSK3b wt transfection increases the percentage of motile mitochondria (D–F) compared to pcDNA3 transfection (F1,18=4.117;
p=0.046) (A–C). Blue, yellow and green triangles label different individual motile mitochondria respectively. G–H: Representative kymographs of
pcDNA3- (G), GSK3b wt- (H) transfected axons respectively. I: Quantification of the percentage of motile mitochondria. J–K: Number of anterograde
(J) and retrograde (K) movements is increased after GSK3b transfection (Anterograde: F1,20=9.398; p=0.006) (Retrograde: F1,20=4.114; p=0.049). L–
N: The number of mitochondria was quantified in several axonal segments and normalized by dividing the number of mitochondria by the length of
the axon. L–M: Representative images of MitDsRed in pcDNA3 (L), GSK3b wt (M) transfected primary cultured neurons. N: Quantification of the
number of mitochondria per axonal length unit. Red asterisk: * 0.05.p$0.01; ** 0.01.p$0.001.
doi:10.1371/journal.pone.0027686.g001
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constructs was required. Cells were processed 24–48 h after
transfection.
Animal care. Mice were obtained from the Centro de Biologıı ´a
Molecular ‘‘Severo Ochoa’’ and treated following the guidelines of
Council of Europe Convention ETS123, recently revised as
indicated in the Directive 86/609/EEC. Animal experiments were
performed under protocols (P22/P23) approved by the
Institutional Animal Care and Utilization Committee of the
Centro de Biologı ´a Molecular Severo Ochoa (CEEA-CBM, approval
certificate number SAF2006-02424 issued on October 10, 2006),
Madrid, Spain.
Live-imaging and quantification of axonal transport of
mitochondria
Hippocampal neurons were seeded onto poly-L-lysine-coated
Fluorodish plates (World Precision Instruments, Inc), transfected
with either GSK3b wt-Myc [18], GSK3b negative dominant-Myc
(GSK3bK85) [19], or MitDsRed, and filmed 24 to 48 h after
using a Leica TCS SP2 confocal microscope (Leica Microsystems)
equipped with a 636immersion oil objective. All the cultures were
kept at 37uC using a heating insert on the microscope stage and an
incubating chamber allowing circulation of a controlled CO2
(5%)-air heated mixture for the control of pH. Movies were
generated at 10 frames per second. For measurements of
axonoplasmic transport of mitochondria, axonal processes in
transfected neurons were identified following morphological
criteria, and directionality was determined for each axon. Axonal
mitochondria were registered with an additional digital zoom of
1.76. Time-lapse series of image stacks composed of 5 images
(5126512 px) were taken every 6 sec during 15 min. All 151
images obtained were processed mainly with Leica Confocal
Software. Further image processing, analysis and video compila-
tion (10 frames per second) and edition was done with ImageJ
software (version 1.43K, NIH, USA). Kymographs were generated
with MetaMorph Software (Molecular Devices - MDS Analytical
Technologies). In overexpression experiments, a minimum of 10
axons were analyzed in each condition. The axons recorded were
selected on the basis of detection of MitDsRed fluorescence. After
live-imaging recording, cultures were fixed and immunostained
against Myc-tag in order to ensure that MitDsRed-transfected
axons were effectively co-transfected with GSK3b. Only double-
transfected axons were analyzed. More than 80% of axons
transfected with MitDsRed were also co-transfected with either
GSK3b wt or DN-GSK3b. In all cases a mitochondrion was
considered motile when it moved more than 0.5 mm during 1 min
of recording. Distances and speeds of retrograde and anterograde
transport were measured separately from the corresponding
kymographs, as previously described [20], and no tracking-
plugging was used. The first frame recorded of each video was
digitally processed and thresholded (using Yi algorithm). The
longest distance between any two points along the selection
boundary (Feret’s parameter) was then measured for all mito-
chondria. To ensure equal relevance between axons, indepen-
dently of the number of mitochondria displayed, an average length
was calculated for each neuron and then the mean was calculated
between axons.
Immunocytochemistry
For Phospho-Tau and apoptotic marker detection, double
immunocytochemistry was performed as described previously [18]
by incubating the cells with the following primary antibodies for
2 h: mouse anti-hyperphosphorylated Tau (PHF-1) (1:1000, a kind
gift from Dr. Peter Davis, New York , USA), rabbit-anti cleaved-
caspase 3 (Cell Signaling Technology, Massachusetts, 1:2,000),
rabbit anti-fractin (Becton Dickinson, NJ, USA, 1:2,000) and
Figure 2. Run length and velocity after GSK3b transfection. Anterograde (A) and retrograde (B) run length after GSK3b wt transfection. C–D:
Anterograde (C) and retrograde (D) velocity of mitochondrial transport after GSK3b wt transfection.
doi:10.1371/journal.pone.0027686.g002
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was then detected over 2 h with the following donkey Alexa-
conjugated secondary antibodies as appropriate (1:1000, Molec-
ular Probes, Eugene, OR, US): Anti-rabbit Alexa 647-conjugated,
Anti-mouse Alexa 647-conjugated, Anti-rabbit Alexa 488-conju-
gated and Anti-mouse Alexa 488-conjugated. Cells were counter-
stained for 10 min with DAPI (1:10000, Calbiochem-EMD
Darmstadt, Germany). Stacks of images were obtained in a Zeiss
LSM710 confocal microscope. Stacks were composed by series of
images, each one separated by 0.1 mm (636Oil objective, Digital
Zoom 2). Fluorescence intensity along the axonal process was then
measured using ImageJ software and then divided by the total
axonal length in each stack.
Statistical Analysis
Data were analyzed conducting a one-way ANOVA test for
comparisons between experimental conditions. SPSS 17.0.1
software (SPSS, 1989; Apache Software Foundation) was used
for all the statistical analyses.
Results
GSK3b overexpression increases mitochondrial axonal
transport
To study the impact of GSK3b on mitochondrial axonal
trafficking, we overexpressed GSK3b in cultured hippocampal
neurons. Transfected neurons were video-recorded 6–7 days after
transfection (Figure 1). Overexpression of GSK3b did not alter the
density of axonal mitochondria (F2,29=2.591; p=0.093) (Figure 1
L–M). In agreement with previous studies, 15-min time-lapse
recordings of control neurons (transfected with the empty vector)
revealed that that most mitochondria remained stationary, while
about 25% moved actively within the axons. GSK3b wt
transfection increased the percentage of motile mitochondria
(Figure 1 I) [21]. In an additional characterization, the number of
anterograde and retrograde movements were measured for each
sample (Figure 1 J and 1 K, respectively). The marked increase in
motile mitochondria after GSK3b overexpression accounts for
both the anterograde and retrograde directions (Figure 1 J and 1
K, respectively). Finally, GSK3b overexpression did not signifi-
cantly alter the distance travelled by single motile mitochondria
(Figure 2 A and 2 B) or their velocity (Figure 2 C and 2 D), in
either the anterograde (Figure 2 A and 2 C) or retrograde (Figure 2
B and 2 D) directions. We thus conclude that GSK3 overexpres-
sion essentially leads to an increase in the number of motile
mitochondria.
GSK3b kinase activity regulates the number of
transported mitochondria and their velocity
To study whether GSK3b kinase activity is required for the
above effects, we transfected neurons with a construct expressing a
dominant-negative GSK3b variant lacking kinase activity (DN-
Figure 3. Effects of the absence of GSK3b activity. A: Dominant negative GSK3b K85 (DN- GSK3b) transfection reduces the percentage of
motile mitochondria (F1,16=16.794; p=0.001). B: Number of anterograde movements after DN-GSK3b transfection is increased compared to
pcDNA3-transfected neurons (F1,16=10.085; p=0.007). C: Number of retrograde movements after DN-GSK3b transfection is decreased compared to
that of pcDNA3-transfected neurons (F1,17=32.054; p=0.001). D–E: Absence of GSK3b activity modifies the average anterograde (F1,18=5.297;
p=0.034) but not the retrograde run length. F–G: The lack of GSK3b activity decreases the velocity of anterograde mitochondrial trafficking (F)
(F1,17=4.257; p=0.048) whereas it does not modify the speed of individual retrograde movements (G). H: The number of mitochondria per length
unit remains unchanged after DN-GSK3b transfection. Asterisk: * 0.05.p$0.01; ** 0.01.p$0.001.
doi:10.1371/journal.pone.0027686.g003
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density of axonal mitochondria (Figure 3 H). The GSK3b-
mediated increase in mitochondrial motility was not observed
when neurons were transfected with the DN-GSK3b variant.
Indeed, opposite effects were found (Figure 3). Again, this effect
accounted for both the anterograde (Figure 3 B, 3 D and 3 F) and
retrograde (Figure 3 C, 3 E and 3 G) directions of transport.
Moreover, transfection with DN-GSK3b resulted in the opposite
effects, thereby leading to a marked reduction in the number of
motile mitochondria compared to control neurons (Figure 3 A). In
addition, the number of anterograde (Figure 3 B) and retrograde
(Figure 3 C) movements was reduced due to DN-GSK3b
transfection. Similarly, the absence of GSK3b activity modified
the average anterograde but not the retrograde run length
travelled by individual mitochondria (Figure 3 D and 3 E
respectively). Finally, the lack of GSK3b activity decreased the
velocity of anterograde mitochondrial trafficking (Figure 3 F) but
did not modify the speed of individual retrograde movements
(Figure 3 G). Taken together, these findings suggest that GSK3b
activity regulates not only the number of motile mitochondria
through the axon but also the trafficking speed of these
mitochondria. Finally, the absence of GSK3b activity did not
modify the general morphology or appearance of the transfected
neurons (Figure 4). Similarly, axonal mitochondria showed similar
densities (Figure 3 H), morphology, size, roundness and absence of
aggregation in all the experimental conditions tested (Figure 4 Y-
AE). Similarly, general morphology, nuclear chromatin conden-
sation, neurite number and appearance remained unchanged after
co-transfection of MitDsRed and pcDNA3 (Figure 4 A–H),
GSK3b wt (I–P) or DN-GSK3b (Q–X). In line with this, DN-
GSK3b transfection did not induce apoptotic processes, as can be
observed in Supplementary Figure S1.
Tau protein is required for the effects of GSK3b
overexpression on mitochondrial trafficking
Axonal mitochondrial transport requires the association be-
tween microtubules and mitochondria [22]. Two protein super-
families, the kinesins and dyneins, serve as molecular motors for
anterograde or retrograde transport of mitochondria, respectively.
The binding of these proteins to microtubules is regulated by
microtubule-associated proteins (MAPs), such as tau [23] and
MAP1B [24]. In fact, it has been proposed that the presence of
MAPs increases mitochondria pausing [24]. Tau phosphorylation
by GSK3 could result in a decrease in the interaction of this MAP
with microtubules [21,25] and it may increase the binding of
motors to microtubules and the number of motile mitochondria.
To test whether Tau, a GSK3 substrate, is involved in the effects
described above, we first analyzed the levels of Tau phosphory-
lation after GSK3b overexpression, by using PHF-1 and AT180
antibodies [18] (Figure 5). A dramatic increase in tau phosphor-
ylation was detected when GSK3b was overexpressed (Figure 5 A).
Representative images of AT180 (Figure 5 O–T) and PHF-1
(Figure 5 I–O) hyperphosphorylated tau in pcDNA3- and GSK3b-
transfected neurons can be observed in Figure 5. Thus, we
examined the contribution of GSK3b to mitochondria transport in
the absence of tau. For this purpose, we transfected the GSK3b
expression vector in Tau (2/2) neurons and wild-type (WT)
littermate controls. In the absence of tau, an increase in the
number of motile mitochondria was observed in control neurons
(Figure 5 B). Moreover, in neurons lacking tau protein, GSK3b
overexpression did not result in changes in any of the
mitochondrial trafficking parameters measured (Figure 5 B–F),
in contrast to WT neurons overexpressing GSK3b (see Figure 3).
Thus, similar values for mitochondria run length (Figure 5 E, 5 F),
anterograde (Figure 5 C) and retrograde (Figure 5 D) velocities,
Figure 4. Cell morphology and appearance does not change after transfection with -GSK3b wt or DN-GSK3b. A–X: The general
morphology, nuclear chromatin condensation, neurite number and appearance remains unchanged after co-transfection of MitDsRed and pcDNA3
(A–H), GSK3b wt (I–P) or DN-GSK3b (Q–X). MitDsRed: red; DAPI: Green; myc: Blue. White triangles label the soma of each individual tranfected
neuron. Y-AE: Mitochondrial morphology, roundness and density do not change after transfection with GSK3b wt (AA–AB) or DN-GSK3b (AC–AD)
compared to pcDNA3-transfected neurons (Y–Z). In Z, AB and AD high magnification of several mitochondria represented respectively in Y, AA and
AC can be observed. MitDsRed: Red. AE: Quantification of mitochondrial size.
doi:10.1371/journal.pone.0027686.g004
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H) movements were found in the absence and in the presence of
GSK3 overexpression in Tau-deficient neurons. These data
strongly suggest that the effects of GSK3b on mitochondrial
trafficking are largely mediated by the MAP protein Tau.
Thus, an increase in the number of motile mitochondria was
found in the absence of tau protein (Figure 5 B). This effect was
similar to that observed upon an increase in GSK3b activity
(Figure 1 I). Furthermore, in the absence of tau, no differences in
axonal transport rates were found, as previously reported [26]. In
contrast, in the presence of increased GSK3b activity, we detected
differences in the retrograde trafficking velocity of mitochondria.
In this regard, proteins other than tau could be involved in the
GSK3b-dependent effect on retrograde axonal mitochondria
transport.
Discussion
Here we found that overexpression of GSK3b in cultured
neurons results in an increase in the number of axonal motile
mitochondria. About two thirds of the total axonal mitochondria
remained stationary in our neuronal cultures but this number
markedly decreased when GSK3b was overexpressed. There is no
clear explanation for the possible function of mitochondria
pausing. Axonal transport of healthy mitochondria is required to
carry them to the growth cones, or to the synapses, where the
presence of these organelles is required [27,28] It has been
suggested that when growth cone activity is low, mitochondria
switch to retrograde movement [27]. Also, dysfunctional mito-
chondria are retrogradely transported towards the cell body to
undergo repair, a process that occurs by fusion with healthy
mitochondria or degradation by mitophagy [29,30,31]. Thus, an
increase in stationary mitochondria may result in the lack of all, or
some, of these functions. Moreover, mitochondrial pausing has
been related to enhanced neurotransmission and Ca2
+ elevations,
thereby supplying the energy required for local excitability events
[32,33]. Here we demonstrate that the expression of GSK3b
facilitates the movement of mitochondria. On the basis of this
observation, we propose that GSK3 levels and activity modulate
some of the crucial events mentioned above, as previously
demonstrated [34].
Here we found that the effects of GSK3 overexpression on
mitochondrial trafficking were abolished in Tau (2/2) neurons,
thereby indicating that the effects of this kinase are mediated by its
action on the modification of Tau. Moreover, it is well known that
MAPs like tau protein share and compete with microtubule motors
for the same binding sites to microtubules [35,36,37]. Indeed, we
found that GSK3b overexpression results in an increase in tau
phosphorylation and a decrease of tau bound to microtubules.
We also observed some differences in anterograde (decrease)
and retrograde (increase) rates when GSK3b activity was
decreased with the DN-GSK3 construct, which also acts as a
dominant negative [19,38]. In this way, it has recently been
demonstrated that mitochondrial axonal transport is specifically
inhibited by treatment with the GSK3 inhibitor lithium [39].
There are several possible explanations for these findings. Tau
interferes with the binding of motor proteins, like kinesin, to
microtubules [16,23,40] and there is a gradient of tau along the
axon, with the highest levels found at the distal part of the axon
[41], which could explain the detachment of kinesin close to the
synapses. This observation might explain the fall in anterograde
velocity observed when GSK3b activity decreased. Moreover, Tau
protein not only competes with molecular motors for binding to
microtubules [23] but it has also been suggested that tau inhibits
kinesin activity [16,35,42], through a mechanism involving tau
phosphorylation [43].
A similar gradient has been found for GSK3-phosphorylated
MAP1B [44]. Although the functional consequences of this
phosphorylation are unknown, some modes of phosphorylation
may favor the binding of MAP1B to microtubules [45,46].
Furthermore, a higher competition of MAP1B with dynein for
microtubule binding sites has been proposed [24]. Thus, the
alterations in retrograde mitochondrial transport reported here
could be mediated by changes in the phosphorylation of MAP1B
induced by GSK3b.
In summary, here we have shown that GSK3b activity
participates in the relief mitochondrial pausing, and that this
relief depends largely on Tau proteins. In addition, we
demonstrate that an increase in GSK3 activity results in
differences in trafficking velocities of axonal mitochondria, which
we propose to be dependent on both Tau and other MAP
proteins.
Supporting Information
Figure S1 Transfection with DN-GSK3b does not induce
apoptotic processes. A–O: Immunocytochemistry against
Caspase 3. DN-GSK3b transfection does not induce apoptosis.
As can be seen in the images, apoptotic cells (white asterisk) can be
observed among the field, but no-colocalization with MitDsRed or
with myc can be appreciated. A double transfected neuron is
labeled with a white arrow. A–E and K–O: High magnification
images of the squared area in F–J. P–Y: Immunocytochemistry
against Fractin (Caspase-3 cleaved fragment of actin). Apoptotic
cells (white asterisk) can be observed among the field, but no
colocalization with MitDsRed or with myc can be appreciated. A
double transfected neuron is labeled with a white arrow. U–Y:
High magnification images of the squared area in P–T.
(TIF)
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Figure 5. GSK3b overexpression effects are mediated by Tau phosphorylation. A: Tau phosphorylation is increased after GSK3b
overexpression (F1,18=20.987; p=0.0001). B: Percentage of motile mitochondria in Tau (2/2) neurons is increased compared to wt (F1,26=9.34;
p=0.001) whereas GSK3b overexpression in Tau (2/2) neurons does not modify this parameter. C–D: Anterograde (C) or retrograde (D)
mitochondrial velocity in the absence of tau and after overexpression of GSK3b. E–H: Tau absence does not modify mitochondria run length but
increases the number of anterograde and retrograde movements. E–F: Neither anterograde (E) nor retrograde (F) run length is modified in the
absence of Tau or after overexpression of GSK3b. G–H: Number of anterograde (G) and retrograde (H) movements in the absence of tau and after
overexpression of GSK3b in Tau (2/2) neurons. Tau absence increases the number of both anterograde (F1,26=9.164; p=0.001) and retrograde
movements (F1,28=4.992; p=0.015) compared to wt neurons. I–T: Phosphorylation of tau is increased after GSK3b transfection. PHF-1 staining in
GSK3b-( L–N) and pcDNA3-transfected axons (I–K). PHF-1: Green; myc: Blue. Similarly, AT180 staining is also increased in GSK3b-( R–T) compared to
pcDNA3-transfected axons (O–Q). AT180: Green; myc: Blue. Red triangles indicate pcDNA3-transfected axons. White triangles label GSK3b-transfected
axons. Red asterisk: * 0.05.p.0.01; ** 0.01.p$0.001; *** 0.001.p$0.0001.
doi:10.1371/journal.pone.0027686.g005
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